DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for multiple myeloma — screening already-approved drugs against its 48-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMultiple myeloma maps to a 48-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedBortezomibApproved drug
Structures already discussed alongside multiple myeloma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Crystal structure of the Lon-like protease MtaLonC — Bortezomib has a real, experimentally solved structure in complex with this target (PDB 4FWD, 2.03 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet bo2drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4FWD · 2.03 Å · ligand Bortezomib (BO2). Experimental structure, not a prediction.
What the evidence adds up to
Multiple myeloma remains incurable despite two decades of drug approvals that have extended survival. A 2020 review notes that the growing number of available agents has made treatment selection complex, because few head-to-head trials compare the combinations used at each disease stage. A 2012 review states that nearly all patients eventually relapse, and that frontline and relapsed/refractory treatment now typically pairs dexamethasone with the proteasome inhibitor bortezomib or an immunomodulatory drug (thalidomide or lenalidomide). Alkylating agents (melphalan, cyclophosphamide, bendamustine) and pegylated liposomal doxorubicin have shown high response rates and prolonged remissions when combined with these agents, and maintenance therapy, especially with lenalidomide, has emerging supportive data.
A 2022 experimental study tested a resynthesised belinostat derivative, compound 7f, against multiple myeloma cells. The derivative had an IC50 of 0.318 ± 0.049 μM and showed more potent inhibition of histone deacetylase 6 catalytic activity than belinostat itself. When combined with bortezomib, 7f produced a strong synergistic interaction (combination index 0.26), compared with a combination index of 0.36 for belinostat plus bortezomib. These are in vitro data only; no patient outcomes are reported.
A 2019 book-length update covers epidemiology, genetic targets, resistance mechanisms, angiogenesis, stem cell transplantation, radiotherapy, infectious complications, and management in resource-poor settings, but provides no single new trial result that changes the incurable status of the disease. What is still missing is randomised evidence that any of these newer combinations or derivatives improve overall survival over current standards, as well as trials designed to stratify patients by genetic risk or prior treatment history. Funding for such comparative trials, rather than for further single-arm or preclinical work, is needed to move beyond the current state where multiple effective drugs exist but the optimal sequence and combination remain unknown.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancers · 2020 · 39 citations · open access
Recent Advances in the Treatment of Patients with Multiple Myeloma
AbstractIn the past 20 years, few diseases have seen as great progress in their treatment as multiple myeloma. With the approval of many new drugs and the limited availability of clinical trials comparing head-to-head the different possible combinations, the choice of the best treatments at each stage of the disease becomes complex as well as crucial since multiple myeloma remains incurable. This article presents a general description of the novelties of the whole treatment of multiple myeloma, from induction in the newly diagnosed patient through the role of hematopoietic stem cell transplantation and maintenance treatment until early and late relapses, including a section on recently approved drugs as well as novel drugs and immunotherapy in advanced stages of research, and that will surely play a relevant role in the treatment of this devastating disease in the coming years.
Current Opinion in Supportive and Palliative Care · 2012 · 20 citations
Multiple myeloma
AbstractPURPOSE OF REVIEW: Nearly all patients with multiple myeloma will eventually relapse; and, thus, it is critical to identify new treatments that increase therapeutic options for these patients. This review highlights the newest approaches with already approved drugs for treating this common B-cell malignancy. RECENT FINDINGS: Most patients with multiple myeloma in both the frontline and relapsed/refractory settings are now treated with a combination of dexamethasone with the proteasome inhibitor bortezomib and/or an immunomodulatory agent thalidomide or lenalidomide. However, alkylating agents including melphalan, cyclophosphamide and most recently bendamustine as well as anthracyclines, especially the pegylated liposomal doxorubicin, have shown high response rates and prolonged remissions when combined with these agents. There are emerging data showing the importance of maintenance therapy especially with lenalidomide. Because of the marked improvement in survival of multiple myeloma during the past decade, there has been a renewed emphasis on developing therapies that are not only effective but also well tolerated. Alternative dosing, scheduling and routes of administration of already approved drugs have proven effective in accomplishing these goals. SUMMARY: The availability of drugs with different mechanisms that produce anti-multiple myeloma effects and also show synergistic effects has paved the way for more effective and safer combinations and led to multiple myeloma patients living longer with improved quality of lives.
Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies
Abstract= 0.318 ± 0.049 μM). Furthermore, we also confirmed the inhibitory activity of 7f in a cellular model. Additionally, we found that the inhibitory activity of 7f against histone deacetylase 6 catalytic activity (HDAC6) is more potent than that of belinostat. Finally, we observed the strong synergistic interaction between the derivative 7f and the proteasome bortezomib inhibitor (CI = 0.26), while belinostat and bortezomib showed synergism with a CI value of 0.36. Taken together, the above results suggest that 7f is a promising HDAC inhibitor deserving further investigation.
IntechOpen eBooks · 2019 · 13 citations · open access
Update on Multiple Myeloma
AbstractThis book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
